GOLM1 and melanoma: We revealed that enhanced GOLPH2 and GOLPH3 immunoreactivity in melanoma cells is associated with shorter cancer-specific overall survival (CSOS) and disease-free survival (DFS) in the whole group of patients (Figure 4 and Figure 5).